AR038332A1 - Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion - Google Patents
Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacionInfo
- Publication number
- AR038332A1 AR038332A1 ARP030100254A ARP030100254A AR038332A1 AR 038332 A1 AR038332 A1 AR 038332A1 AR P030100254 A ARP030100254 A AR P030100254A AR P030100254 A ARP030100254 A AR P030100254A AR 038332 A1 AR038332 A1 AR 038332A1
- Authority
- AR
- Argentina
- Prior art keywords
- metabolites
- phenoxy
- amino
- methyl
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 239000002207 metabolite Substances 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 239000002253 acid Substances 0.000 title 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 abstract 3
- 125000003352 4-tert-butyl benzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1C([H])([H])*)C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 abstract 1
- 208000010392 Bone Fractures Diseases 0.000 abstract 1
- 208000001132 Osteoporosis Diseases 0.000 abstract 1
- 238000001514 detection method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/89—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
- C07D213/71—Sulfur atoms to which a second hetero atom is attached
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pyridine Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Metabolitos del ácido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil) amino)metil}fenoxi)acético y sales de los mismos, su uso en la detección del tratamiento con dicho compuesto, composiciones farmacéuticas de estos compuestos que son útiles en el tratamiento de fracturas óseas y osteoporosis.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35374802P | 2002-01-31 | 2002-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR038332A1 true AR038332A1 (es) | 2005-01-12 |
Family
ID=27663249
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030100254A AR038332A1 (es) | 2002-01-31 | 2003-01-29 | Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6852863B2 (es) |
| EP (1) | EP1470109A1 (es) |
| JP (1) | JP2005521668A (es) |
| KR (1) | KR20040077884A (es) |
| CN (1) | CN1625549A (es) |
| AP (1) | AP2004003094A0 (es) |
| AR (1) | AR038332A1 (es) |
| BR (1) | BR0307339A (es) |
| CA (1) | CA2473984A1 (es) |
| EA (1) | EA200400724A1 (es) |
| EC (1) | ECSP045215A (es) |
| GB (1) | GB2400100B (es) |
| HN (1) | HN2003000051A (es) |
| HR (1) | HRP20040683A2 (es) |
| HU (1) | HUP0500012A2 (es) |
| IL (1) | IL162167A0 (es) |
| IS (1) | IS7281A (es) |
| MA (1) | MA27169A1 (es) |
| MX (1) | MXPA04004960A (es) |
| NO (1) | NO20043569L (es) |
| OA (1) | OA12760A (es) |
| PA (1) | PA8564601A1 (es) |
| PE (1) | PE20030978A1 (es) |
| PL (1) | PL371982A1 (es) |
| TN (1) | TNSN04138A1 (es) |
| TW (1) | TW200302080A (es) |
| UY (1) | UY27632A1 (es) |
| WO (1) | WO2003064391A1 (es) |
| ZA (1) | ZA200404067B (es) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
| US7666330B2 (en) * | 2005-04-20 | 2010-02-23 | Lg Chem, Ltd. | Additive for non-aqueous electrolyte and secondary battery using the same |
| RS20090002A (sr) * | 2006-07-28 | 2010-06-30 | Pfizer Products Inc. | Agonisti ep2 |
| US20110105602A2 (en) | 2007-03-08 | 2011-05-05 | Daria Mochly-Rosen | Mitochondrial Aldehyde Dehydrogenase-2 Modulators and Methods of Use Thereof |
| EP2002834A1 (de) * | 2007-06-13 | 2008-12-17 | Bayer Schering Pharma Aktiengesellschaft | Aryl/Hetarylamide als Modulatoren des EP2-Rezeptors |
| DK2264009T3 (en) * | 2008-03-12 | 2019-04-15 | Ube Industries | PYRIDYLAMINE ACEDIC ACID COMPOUND |
| EP2149552A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors |
| EP2149554A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma Aktiengesellschaft | Indolylamide als Modulatoren des EP2-Rezeptors |
| EP2149551A1 (de) | 2008-07-30 | 2010-02-03 | Bayer Schering Pharma AG | N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors |
| CN102209541B (zh) | 2008-09-08 | 2016-05-18 | 小利兰·斯坦福大学托管委员会 | 醛脱氢酶活性调节剂和其使用方法 |
| CN102202669A (zh) | 2008-10-28 | 2011-09-28 | 利兰·斯坦福青年大学托管委员会 | 醛脱氢酶调节剂及其使用方法 |
| PL2415763T3 (pl) | 2009-03-30 | 2016-05-31 | Ube Industries | Kompozycja farmaceutyczna do leczenia lub profilaktyki jaskry |
| DE102009049662A1 (de) | 2009-10-13 | 2011-04-14 | Bayer Schering Pharma Aktiengesellschaft | 2,5-Disubstituierte 2H-Indazole als EP2-Rezeptor-Antagonisten |
| US10457659B2 (en) | 2011-04-29 | 2019-10-29 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions and methods for increasing proliferation of adult salivary stem cells |
| TW201326154A (zh) | 2011-11-28 | 2013-07-01 | 拜耳知識產權公司 | 作為ｅｐ２受體拮抗劑之新穎２ｈ－吲唑 |
| CN105358531B (zh) | 2013-03-14 | 2017-11-14 | 利兰-斯坦福大学初级学院的董事会 | 线粒体醛脱氢酶‑2调节剂和其使用方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA67754C2 (uk) * | 1997-10-10 | 2004-07-15 | Пфайзер, Інк. | Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти) |
-
2003
- 2003-01-20 CN CNA038029952A patent/CN1625549A/zh active Pending
- 2003-01-20 GB GB0413967A patent/GB2400100B/en not_active Expired - Fee Related
- 2003-01-20 BR BR0307339-4A patent/BR0307339A/pt not_active IP Right Cessation
- 2003-01-20 EA EA200400724A patent/EA200400724A1/ru unknown
- 2003-01-20 KR KR10-2004-7011618A patent/KR20040077884A/ko not_active Ceased
- 2003-01-20 EP EP03700072A patent/EP1470109A1/en not_active Withdrawn
- 2003-01-20 HU HU0500012A patent/HUP0500012A2/hu unknown
- 2003-01-20 JP JP2003564014A patent/JP2005521668A/ja active Pending
- 2003-01-20 WO PCT/IB2003/000121 patent/WO2003064391A1/en not_active Ceased
- 2003-01-20 HR HR20040683A patent/HRP20040683A2/hr not_active Application Discontinuation
- 2003-01-20 OA OA1200400198A patent/OA12760A/en unknown
- 2003-01-20 IL IL16216703A patent/IL162167A0/xx unknown
- 2003-01-20 CA CA002473984A patent/CA2473984A1/en not_active Abandoned
- 2003-01-20 AP APAP/P/2004/003094A patent/AP2004003094A0/en unknown
- 2003-01-20 MX MXPA04004960A patent/MXPA04004960A/es unknown
- 2003-01-20 PL PL03371982A patent/PL371982A1/xx not_active Application Discontinuation
- 2003-01-24 TW TW092101619A patent/TW200302080A/zh unknown
- 2003-01-28 PE PE2003000086A patent/PE20030978A1/es not_active Application Discontinuation
- 2003-01-28 HN HN2003000051A patent/HN2003000051A/es unknown
- 2003-01-29 US US10/353,671 patent/US6852863B2/en not_active Expired - Fee Related
- 2003-01-29 AR ARP030100254A patent/AR038332A1/es unknown
- 2003-01-30 UY UY27632A patent/UY27632A1/es not_active Application Discontinuation
- 2003-01-30 PA PA20038564601A patent/PA8564601A1/es unknown
-
2004
- 2004-05-21 IS IS7281A patent/IS7281A/is unknown
- 2004-05-25 ZA ZA200404067A patent/ZA200404067B/en unknown
- 2004-07-21 MA MA27796A patent/MA27169A1/fr unknown
- 2004-07-27 TN TNP2004000138A patent/TNSN04138A1/fr unknown
- 2004-07-30 EC EC2004005215A patent/ECSP045215A/es unknown
- 2004-08-26 NO NO20043569A patent/NO20043569L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| TW200302080A (en) | 2003-08-01 |
| NO20043569D0 (no) | 2004-08-26 |
| CA2473984A1 (en) | 2003-08-07 |
| GB2400100A (en) | 2004-10-06 |
| AP2004003094A0 (en) | 2004-09-30 |
| PE20030978A1 (es) | 2003-11-19 |
| PA8564601A1 (es) | 2003-09-05 |
| GB2400100B (en) | 2006-04-12 |
| US20030216445A1 (en) | 2003-11-20 |
| US6852863B2 (en) | 2005-02-08 |
| PL371982A1 (en) | 2005-07-11 |
| NO20043569L (no) | 2004-08-26 |
| GB0413967D0 (en) | 2004-07-28 |
| EP1470109A1 (en) | 2004-10-27 |
| IS7281A (is) | 2004-05-21 |
| KR20040077884A (ko) | 2004-09-07 |
| WO2003064391A1 (en) | 2003-08-07 |
| MA27169A1 (fr) | 2005-01-03 |
| UY27632A1 (es) | 2003-08-29 |
| CN1625549A (zh) | 2005-06-08 |
| MXPA04004960A (es) | 2005-04-08 |
| HUP0500012A2 (hu) | 2005-04-28 |
| ZA200404067B (en) | 2005-08-29 |
| ECSP045215A (es) | 2004-09-28 |
| BR0307339A (pt) | 2004-12-07 |
| JP2005521668A (ja) | 2005-07-21 |
| TNSN04138A1 (fr) | 2007-03-12 |
| EA200400724A1 (ru) | 2004-12-30 |
| OA12760A (en) | 2006-07-04 |
| IL162167A0 (en) | 2005-11-20 |
| HN2003000051A (es) | 2003-09-24 |
| HRP20040683A2 (en) | 2004-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR038332A1 (es) | Compuestos que son metabolitos del acido (3-{[(4-terc-butilbencil)-(piridin-3-sulfonil)amino]metil}fenoxi) acetico, composiciones farmaceuticas que los contienen, y procedimiento de determinacion | |
| ECSP045520A (es) | Metodos de tratamiento con inhibidores de la ptec y agentes antihipertensivos | |
| BRPI0417684A (pt) | composto, composição farmacêutica, e, uso de um composto | |
| AR023463A1 (es) | Uso de compuestos de azetidinona | |
| DE60314623D1 (de) | Substituierte pyrazolopyrimidine | |
| CY1106468T1 (el) | Υποκατεστημενα παραγωγα κυκλοεξανο-1,4-διαμινης | |
| ECSP055746A (es) | Antagonistas de cgrp elegidos, procedimiento para su preparación, así como su empleo como medicamentos | |
| AR024138A1 (es) | Inhibidores de la proliferacion celular | |
| CY1108101T1 (el) | Ενωσεις πυριμιδινης και η χρηση τους στην παρασκευη ενος τριαζολο-πυριμιδιν καρβα νουκλεοζιτη | |
| AR011116A1 (es) | Compuesto derivado de n-hidroxi-beta-sulfonil propionamida y composicion farmaceutica que lo contiene | |
| BR9916894A (pt) | ácidos sulfohidroxâmicos e sulfohidroxamatos eseu uso como inibidores de mek | |
| ATE327977T1 (de) | Tetrahydrochinolin-derivate als crth2 antagonisten | |
| UY27740A1 (es) | Nuevos compuestos | |
| PA8583401A1 (es) | Nuevos compuestos de triazol como inhibidores del factor de crecimiento transformante (tgf) | |
| SV2004001690A (es) | Nuevos derivados de fluoroglicosidos heterociclicos, medicamentos que contienen estos compuestos, y el uso de los mismos | |
| BR0309546A (pt) | Composto, composição farmacêutica que compreende o mesmo, processo para a sua preparação e utilização e método para tratamento profilático ou terapêutico de diabetes do tipo ii | |
| EA200500312A1 (ru) | Новые спироконденсированные хиназолиноны и их применение в качестве ингибиторов фосфодиэстераз | |
| ECSP088821A (es) | Derivados de tioxantina y su uso como inhibidores de la mpo | |
| CY1113533T1 (el) | Ετεροαρυλο-υποκατεστημενα παραγωγα κυκλοεξυλο-1,4-διαμινης | |
| DE60301339D1 (de) | Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen | |
| PA8586801A1 (es) | Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso | |
| CY1105247T1 (el) | Υποκατεστημενα παραγωγα c- κυκλοεξυλομεθυλαμινης | |
| BR0307903A (pt) | derivados de arilsulfona | |
| EA200500830A1 (ru) | Производные имидазохинолина в качестве лигандов аденозиновых a3 рецепторов | |
| ATE507209T1 (de) | Referenzstandard zur charakterisierung von rosuvastatin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |